# Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg

> **NCT01358708** · PHASE3 · TERMINATED · sponsor: **Forest Laboratories** · enrollment: 26 (actual)

## Conditions studied

- Diarrhea-predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** LACTEOL® 340 mg
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT01358708
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Administrative reasons
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358708, "Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01358708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*